Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$118.30

-0.99 (-0.83%)

, NBIX

Neurocrine

$90.59

-1.84 (-1.99%)

08:03
03/13/18
03/13
08:03
03/13/18
08:03

AbbVie says Phase 3 ELARIS UF-II study of elagolix met primary endpoint

AbbVie (ABBV) in cooperation with Neurocrine Biosciences (NBIX), announced that the Phase 3 ELARIS UF-II study of elagolix met its primary endpoint. Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone therapy, reduced heavy menstrual bleeding with 76.2% of women with uterine fibroids achieving clinical response compared to placebo, as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50% or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints at month six.

ABBV

AbbVie

$118.30

-0.99 (-0.83%)

NBIX

Neurocrine

$90.59

-1.84 (-1.99%)

  • 13

    Mar

  • 13

    Mar

  • 20

    Mar

ABBV AbbVie
$118.30

-0.99 (-0.83%)

02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Overweight
Piper says 'hard to quibble with' elagolix efficacy, keeps AbbVie at Overweight
After AbbVie reported that one of its two Phase 3 trials of elagolix in patients with uterine fibroids met its primary efficacy endpoint and all ranked secondary endpoints, Piper Jaffray analyst Christopher Raymond said it was "hard to quibble with the efficacy data." He expects to see 12-month data from both trials later this year or early next, which would set up for a potential uterine fibroids launch in 2020. Raymond, who said he "would not be shocked" if his revenue estimates in this indication prove conservative, keeps an Overweight rating on AbbVie.
02/22/18
NEED
02/22/18
NO CHANGE
Target $110
NEED
Buy
Neurocrine price target raised to $110 from $95 at Needham
Needham analyst Alan Carr raised his price target on Neurocrine (NBIX) to $110 and kept his Buy rating on the stock. Carr cites the positive top-line results from the first of two phase 3 trials of elagolix by Neurocrine's collaborator AbbVie (ABBV) as well as last week's disclosure that the FDA will not require another phase 3 efficacy trial for opicapone. The analyst notes that the added timeline clarity will likely translate into the opicapone NDA submission in the first half of 2019 and a launch in mid-2020.
02/23/18
OPCO
02/23/18
NO CHANGE
Target $110
OPCO
Outperform
Neurocrine 'going for gold,' has 'Midas Touch,' says Oppenheimer
Oppenheimer analyst Jay Olson raised his price target on Neurocrine shares to $110 from $100, citing the positive Phase 3 study results for elagolix in the treatment of uterine fibroids by Neurocrine's collaborator AbbVie (ABBV). Additionally, Olson cited last week's disclosure that the FDA will not require a Phase 3 study in the U.S. for opicapone for the price target increase. Olson told investors in a research note called "Going for Gold -- This Team Has the Midas Touch" that both of these updates are seen as "key de-risking events" and raise the probability of success for both elagolix and opicapone to 90% from 60%. Olson has an Outperform rating on Neurocrine shares.
03/08/18
PIPR
03/08/18
NO CHANGE
Target $138
PIPR
Overweight
AbbVie shares can 'continue to work,' says Piper Jaffray
After hosting a meeting with investors at AbbVie's (ABBV) headquarters this week, Piper Jaffray analyst Christopher Raymond believes the shares can "continue to work." The analyst believes the stock can continue outperforming on "solid" commercial and clinical performance. Management expressed no urgency for a larger commercial or late-stage acquisition, Raymond tells investors in a research note. The analyst says he's glad he never wrote that AbbVie for Biogen (BIIB) research note. He keeps an Overweight rating on AbbVie.
NBIX Neurocrine
$90.59

-1.84 (-1.99%)

02/14/18
OPCO
02/14/18
NO CHANGE
Target $100
OPCO
Outperform
Neurocrine price target raised to $100 from $95 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $100 from $95 to reflect Q4 financial results, management guidance on expenses and profitability. The analyst reiterates an Outperform rating on the shares.
02/20/18
LEER
02/20/18
NO CHANGE
Target $96
LEER
Outperform
Neurocrine price target raised to $96 from $90 at Leerink
Leerink analyst Paul Matteis raised his price target Neurocrine to $96 from $90 to reflect the company's positive update on opicapone, Q4 results, and bullish commentary from management at his firm recent investor dinner. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

LGIH

LGI Homes

$54.89

-2.27 (-3.97%)

19:02
03/19/19
03/19
19:02
03/19/19
19:02
Hot Stocks
LGI Homes announces new community in Las Vegas »

LGI Homes, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01
Hot Stocks
Sage says Zulresso approval represents 'game-changing approach' to PPD »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

QTRX

Quanterix

$24.59

-0.01 (-0.04%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Quanterix »

Quanterix files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIHS

Senmiao Technology

$4.71

-0.275 (-5.52%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Senmiao Technology »

Senmiao Technology files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:54
03/19/19
03/19
18:54
03/19/19
18:54
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

PULM

Pulmatrix

$1.70

-0.09 (-5.03%)

18:53
03/19/19
03/19
18:53
03/19/19
18:53
Syndicate
Breaking Syndicate news story on Pulmatrix »

Pulmatrix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

SIEN

Sientra

$8.81

-0.4 (-4.34%)

18:51
03/19/19
03/19
18:51
03/19/19
18:51
Recommendations
Sientra analyst commentary  »

Sientra implied costs to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:50
03/19/19
03/19
18:50
03/19/19
18:50
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:45
03/19/19
03/19
18:45
03/19/19
18:45
Hot Stocks
FedEx CEO: Domestic business is pretty good »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

LYFT

Lyft

$0.00

(0.00%)

18:41
03/19/19
03/19
18:41
03/19/19
18:41
Periodicals
Lyft IPO oversubscribed so far, Reuters reports »

Lyft's IPO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

NSTG

NanoString

$24.27

-3.03 (-11.10%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Syndicate
NanoString 4.5M share Secondary priced at $23.00 »

JPMorgan, UBS and Cowen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

GLD

SPDR Gold Shares

$123.39

0.35 (0.28%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Hot Stocks
Breaking Hot Stocks news story on SPDR Gold Shares »

SPDR Gold Shares holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCLH

Norwegian Cruise Line

$56.11

-0.03 (-0.05%)

18:33
03/19/19
03/19
18:33
03/19/19
18:33
Hot Stocks
Norwegian Cruise Line CEO: There is no recession »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NTNX

Nutanix

$38.78

0.425 (1.11%)

18:23
03/19/19
03/19
18:23
03/19/19
18:23
Hot Stocks
Nutanix CEO: Our churn is really small »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 04

    Apr

  • 09

    Jul

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:20
03/19/19
03/19
18:20
03/19/19
18:20
Earnings
FedEx says started FY19 expecting revenue to rise $6B, but will see $4.5B »

This implies FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

18:04
03/19/19
03/19
18:04
03/19/19
18:04
Hot Stocks
FDA approves Sage Therapeutics' Zulresso in PPD treatment »

The FDA approved Zulresso…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:02
03/19/19
03/19
18:02
03/19/19
18:02
Hot Stocks
FedEx says reviewing capital expense plan for FY20 »

Sees FY19 effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

BAYRY

Bayer

$0.00

(0.00%)

17:58
03/19/19
03/19
17:58
03/19/19
17:58
Periodicals
Bayer to face liability in second phase of Roundup trial, Bloomberg says »

Bayer has lost the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

17:57
03/19/19
03/19
17:57
03/19/19
17:57
Hot Stocks
FedEx says higher operating costs likely to continue to impact results »

Says will know about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

GPRO

GoPro

$6.26

0.005 (0.08%)

17:51
03/19/19
03/19
17:51
03/19/19
17:51
Periodicals
GoPro rival China's Insta360 plans 2020 IPO, CNBC says »

GoPro rival Insta360,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$181.50

-0.92 (-0.50%)

, AMZN

Amazon.com

$1,762.45

20.45 (1.17%)

17:47
03/19/19
03/19
17:47
03/19/19
17:47
Hot Stocks
FedEx Co-CEO Carter says Amazon not a threat to future growth »

Says well placed to take…

FDX

FedEx

$181.50

-0.92 (-0.50%)

AMZN

Amazon.com

$1,762.45

20.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 26

    Mar

  • 01

    Apr

  • 02

    Apr

  • 04

    Apr

FRBA

First Bank

$11.41

-0.14 (-1.21%)

17:46
03/19/19
03/19
17:46
03/19/19
17:46
Hot Stocks
First Bank to acquire Grand Bank for $19.4M »

First Bank and Grand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$72.00

0.13 (0.18%)

17:42
03/19/19
03/19
17:42
03/19/19
17:42
Hot Stocks
Cognizant President Rajeev Mehta sells over $1.4M in company shares »

Cognizant President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

ENT

Global Eagle

$1.16

-0.14 (-10.77%)

17:42
03/19/19
03/19
17:42
03/19/19
17:42
Downgrade
Global Eagle rating change  »

Global Eagle downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.